High-Throughput Screening Market 2026-2035
Description
High-Throughput Screening Market Size, Share & Trends Analysis Report by Product and Services (Consumables, Instruments, Services, and Software), by Technology (Cell-Based Assays, Lab-on-a-Chip Technology, and Label-Free Technology), and by Application (Drug Discovery, Biochemical Screening, Life Sciences Research, and Other) Forecast Period, (2026-2035)
Industry Overview
High-throughput screening market valued at $7,200.6 million in 2025 and is projected to reach $12,922.7 million by 2035, growing at a CAGR of 6.1% during the forecast period (2026-2035). The global high-throughput screening market is advancing steadily as pharmaceutical and biotechnology companies intensify efforts to accelerate early-stage drug discovery and optimize compound evaluation processes. Market growth is being reinforced by rising demand for automated screening platforms capable of analyzing thousands to millions of compounds with speed and precision. Increasing integration of robotics, miniaturized assay formats, and data analytics tools is streamlining target validation and hit identification workflows. Additionally, the expanding pipeline of biologics and personalized therapies is driving the need for scalable, high-efficiency screening systems. As organizations prioritize cost-effective and time-efficient discovery strategies, high-throughput screening (HTS) technologies are becoming central to modern research infrastructure.
Market Dynamics
Expanding Drug Discovery Pipelines and Need for Rapid Compound Evaluation
Pharmaceutical and biotechnology companies are managing increasingly complex and diversified drug pipelines, requiring advanced screening platforms to evaluate large compound libraries efficiently. High-throughput screening enables rapid identification of promising candidates while reducing manual intervention and experimental variability. The growing focus on rare diseases, oncology, and immunology research is further elevating the importance of scalable screening systems. Organizations are investing in integrated HTS platforms that combine assay development, automated liquid handling, and real-time data analytics to enhance research productivity. This heightened emphasis on speed and precision is a major driver shaping global market expansion.
Rising Integration of Automation, Robotics, and Data Analytics
Technological advancements in laboratory automation and robotic handling systems are significantly improving throughput capacity and reproducibility. Modern HTS platforms incorporate advanced imaging technologies, microplate readers, and AI-supported analytics to enhance screening accuracy. Cloud-based data management systems are enabling seamless storage, retrieval, and analysis of large experimental datasets. Vendors are also developing modular systems that allow laboratories to scale operations without substantial infrastructure changes. As laboratories seek to improve operational efficiency and reduce error margins, the integration of automation and intelligent analytics continues to strengthen market momentum.
Market Segmentation
In the global high-throughput screening market, the consumables segment is expected to account for the largest market share, driven by the recurring demand for reagents, assay kits, microplates, and laboratory supplies used in screening workflows. Unlike instruments, consumables require continuous replenishment, ensuring a steady revenue stream for market players. The rising number of drug discovery programs, increasing research activities in biotechnology and pharmaceutical companies, and growing adoption of automated screening platforms are significantly fueling demand for high-quality reagents and assay kits. Additionally, advancements in assay chemistries and miniaturization technologies are improving sensitivity, reproducibility, and throughput, further strengthening the consumables segment’s leading position within the overall HTS market.
Drug Discovery: A Key Segment in Market Growth
The drug discovery segment plays a pivotal role in driving growth within the global high-throughput screening market, owing to the increasing need to identify novel therapeutic candidates efficiently and cost-effectively. HTS technologies enable researchers to rapidly screen thousands to millions of compounds against specific biological targets, accelerating lead identification and optimization processes. Growing R&D investments by pharmaceutical and biotechnology companies, rising prevalence of chronic and rare diseases, and expanding biologics and precision medicine pipelines are substantially boosting demand for advanced screening solutions. Furthermore, integration of artificial intelligence, automation, and robotics into screening workflows is enhancing data analysis capabilities and operational efficiency. Collectively, these factors position drug discovery as a primary contributor to overall market expansion.
Regional Outlook
The global high-throughput screening market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Dominates with Advanced Research Infrastructure
North America maintains a leading position in the global high-throughput screening market due to the presence of major pharmaceutical companies, contract research organizations, and well-funded academic research institutions. The region benefits from strong investment in life sciences innovation and advanced laboratory automation technologies. Collaborative partnerships between biotechnology firms and technology providers are further accelerating adoption of sophisticated screening platforms. Access to venture capital funding and government-backed biomedical research programs continues to support infrastructure expansion. These factors collectively reinforce North America’s dominant market share.
Asia-Pacific Emerges as a Rapidly Growing Region
Asia-Pacific is experiencing notable growth in the high-throughput screening market as pharmaceutical manufacturing capacity and R&D investment expand across countries such as China, India, and South Korea. Increasing participation of regional contract research organizations is strengthening demand for scalable screening systems. Government initiatives aimed at boosting domestic drug innovation and clinical research capabilities are encouraging modernization of laboratory infrastructure.
Market Players Outlook
The major companies operating in the global high-throughput screening market Agilent Technologies, Inc., Danaher Corporation, Merck KGaA, Revvity, Inc., Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
Industry Overview
High-throughput screening market valued at $7,200.6 million in 2025 and is projected to reach $12,922.7 million by 2035, growing at a CAGR of 6.1% during the forecast period (2026-2035). The global high-throughput screening market is advancing steadily as pharmaceutical and biotechnology companies intensify efforts to accelerate early-stage drug discovery and optimize compound evaluation processes. Market growth is being reinforced by rising demand for automated screening platforms capable of analyzing thousands to millions of compounds with speed and precision. Increasing integration of robotics, miniaturized assay formats, and data analytics tools is streamlining target validation and hit identification workflows. Additionally, the expanding pipeline of biologics and personalized therapies is driving the need for scalable, high-efficiency screening systems. As organizations prioritize cost-effective and time-efficient discovery strategies, high-throughput screening (HTS) technologies are becoming central to modern research infrastructure.
Market Dynamics
Expanding Drug Discovery Pipelines and Need for Rapid Compound Evaluation
Pharmaceutical and biotechnology companies are managing increasingly complex and diversified drug pipelines, requiring advanced screening platforms to evaluate large compound libraries efficiently. High-throughput screening enables rapid identification of promising candidates while reducing manual intervention and experimental variability. The growing focus on rare diseases, oncology, and immunology research is further elevating the importance of scalable screening systems. Organizations are investing in integrated HTS platforms that combine assay development, automated liquid handling, and real-time data analytics to enhance research productivity. This heightened emphasis on speed and precision is a major driver shaping global market expansion.
Rising Integration of Automation, Robotics, and Data Analytics
Technological advancements in laboratory automation and robotic handling systems are significantly improving throughput capacity and reproducibility. Modern HTS platforms incorporate advanced imaging technologies, microplate readers, and AI-supported analytics to enhance screening accuracy. Cloud-based data management systems are enabling seamless storage, retrieval, and analysis of large experimental datasets. Vendors are also developing modular systems that allow laboratories to scale operations without substantial infrastructure changes. As laboratories seek to improve operational efficiency and reduce error margins, the integration of automation and intelligent analytics continues to strengthen market momentum.
Market Segmentation
- Based on the product and services, the market is segmented into consumables, instruments, services, and software.
- Based on the technology, the market is segmented into cell-based assays, lab-on-a-chip technology, and label-free technology.
- based on the application, the market is segmented into drug discovery, biochemical screening, life sciences research, and other.
In the global high-throughput screening market, the consumables segment is expected to account for the largest market share, driven by the recurring demand for reagents, assay kits, microplates, and laboratory supplies used in screening workflows. Unlike instruments, consumables require continuous replenishment, ensuring a steady revenue stream for market players. The rising number of drug discovery programs, increasing research activities in biotechnology and pharmaceutical companies, and growing adoption of automated screening platforms are significantly fueling demand for high-quality reagents and assay kits. Additionally, advancements in assay chemistries and miniaturization technologies are improving sensitivity, reproducibility, and throughput, further strengthening the consumables segment’s leading position within the overall HTS market.
Drug Discovery: A Key Segment in Market Growth
The drug discovery segment plays a pivotal role in driving growth within the global high-throughput screening market, owing to the increasing need to identify novel therapeutic candidates efficiently and cost-effectively. HTS technologies enable researchers to rapidly screen thousands to millions of compounds against specific biological targets, accelerating lead identification and optimization processes. Growing R&D investments by pharmaceutical and biotechnology companies, rising prevalence of chronic and rare diseases, and expanding biologics and precision medicine pipelines are substantially boosting demand for advanced screening solutions. Furthermore, integration of artificial intelligence, automation, and robotics into screening workflows is enhancing data analysis capabilities and operational efficiency. Collectively, these factors position drug discovery as a primary contributor to overall market expansion.
Regional Outlook
The global high-throughput screening market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Dominates with Advanced Research Infrastructure
North America maintains a leading position in the global high-throughput screening market due to the presence of major pharmaceutical companies, contract research organizations, and well-funded academic research institutions. The region benefits from strong investment in life sciences innovation and advanced laboratory automation technologies. Collaborative partnerships between biotechnology firms and technology providers are further accelerating adoption of sophisticated screening platforms. Access to venture capital funding and government-backed biomedical research programs continues to support infrastructure expansion. These factors collectively reinforce North America’s dominant market share.
Asia-Pacific Emerges as a Rapidly Growing Region
Asia-Pacific is experiencing notable growth in the high-throughput screening market as pharmaceutical manufacturing capacity and R&D investment expand across countries such as China, India, and South Korea. Increasing participation of regional contract research organizations is strengthening demand for scalable screening systems. Government initiatives aimed at boosting domestic drug innovation and clinical research capabilities are encouraging modernization of laboratory infrastructure.
Market Players Outlook
The major companies operating in the global high-throughput screening market Agilent Technologies, Inc., Danaher Corporation, Merck KGaA, Revvity, Inc., Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In June 2025, Thermo Fisher Scientific unveiled the Thermo Scientific Orbitrap Astral Zoom and Orbitrap Excedion Pro mass spectrometers at ASMS 2025. The next-generation systems are designed to deliver increased speed and sensitivity for proteomics and biopharma research, supporting high-throughput omics applications that strengthen screening and target identification workflows.
- In August 2025, Revvity, Inc. launched pHSense reagents to enhance high-throughput internalization studies in drug discovery. The plate-based technology integrates pH-sensitive dye chemistry with time-resolved fluorescence readouts, enabling scalable and reproducible screening of GPCRs and antibody-drug conjugates within automated workflows.
- In September 2025, Revvity, Inc. introduced Living Image Synergy AI software to streamline multimodal preclinical imaging analysis. The AI-enabled platform automates segmentation and quantification processes, reducing manual intervention and increasing throughput across discovery research programs.
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global high-throughput screening market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
269 Pages
- 1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global High-Throughput Screening Market Sales Analysis – Product and Services Technology Application ($ Million)
- High-Throughput Screening Market Sales Performance of Top Countries
- 1.1. Research Methodology
- Primary Research Approach
- Secondary Research Approach
- 1.2. Market Snapshot
- 2. Market Overview and Insights
- 2.1. Scope of the Study
- 2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key High-Throughput Screening Market Trends
- 2.2.2. Market Recommendations
- 2.3. Porter's Five Forces Analysis for the High-Throughput Screening Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes
- 3. Market Determinants
- 3.1. Market Drivers
- 3.1.1. Drivers For Global High-Throughput Screening Market: Impact Analysis
- 3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global High-Throughput Screening Market: Impact Analysis
- 3.3. Market Opportunities
- 3.3.1. Opportunities For Global High-Throughput Screening Market: Impact Analysis
- 4. Competitive Landscape
- 4.1. Competitive Dashboard – High-Throughput Screening Market Revenue and Share by Manufacturers
- High-Throughput Screening Product Comparison Analysis
- Top Market Player Ranking Matrix
- 4.2. Key Company Analysis
- 4.2.1. Agilent Technologies, Inc.
- 4.2.1.1. Overview
- 4.2.1.2. Product Portfolio
- 4.2.1.3. Financial Analysis
- 4.2.1.4. SWOT Analysis
- 4.2.1.5. Business Strategy
- 4.2.2. Danaher Corporation
- 4.2.2.1. Overview
- 4.2.2.2. Product Portfolio
- 4.2.2.3. Financial Analysis
- 4.2.2.4. SWOT Analysis
- 4.2.2.5. Business Strategy
- 4.2.3. Merck KGaA
- 4.2.3.1. Overview
- 4.2.3.2. Product Portfolio
- 4.2.3.3. Financial Analysis
- 4.2.3.4. SWOT Analysis
- 4.2.3.5. Business Strategy
- 4.2.4. Revvity, Inc.
- 4.2.4.1. Overview
- 4.2.4.2. Product Portfolio
- 4.2.4.3. Financial Analysis
- 4.2.4.4. SWOT Analysis
- 4.2.4.5. Business Strategy
- 4.2.5. Thermo Fisher Scientific Inc.
- 4.2.5.1. Overview
- 4.2.5.2. Product Portfolio
- 4.2.5.3. Financial Analysis
- 4.2.5.4. SWOT Analysis
- 4.2.5.5. Business Strategy
- 4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership and Collaboration
- 5. Global High-Throughput Screening Market Sales Analysis by Product and Services ($ Million)
- 5.1. Consumables
- 5.2. Instruments
- 5.3. Services
- 5.4. Software
- 6. Global High-Throughput Screening Market Sales Analysis by Technology ($ Million)
- 6.1. Cell-Based Assays
- 6.2. Lab-on-a-Chip Technology
- 6.3. Label-Free Technology
- 7. Global High-Throughput Screening Market Sales Analysis by Application ($ Million)
- 7.1. Drug Discovery
- 7.2. Biochemical Screening
- 7.3. Life Sciences Research
- 7.4. Other
- 8. Regional Analysis
- 8.1. North American High-Throughput Screening Market Sales Analysis – Product and Services Technology Application Country ($ Million)
- Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
- 8.2. European High-Throughput Screening Market Sales Analysis – Product and Services Technology Application Country ($ Million)
- Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
- 8.3. Asia-Pacific High-Throughput Screening Market Sales Analysis – Product and Services Technology Application Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
- 8.4. Rest of the World High-Throughput Screening Market Sales Analysis – Product and Services Technology Application Country ($ Million)
- Macroeconomic Factors for Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa
- 9. Company Profiles
- 9.1. Agilent Technologies, Inc.
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
- 9.2. Aurora Biomed Inc.
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
- 9.3. Axxam S.p.A.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
- 9.4. Bio-Rad Laboratories, Inc.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
- 9.5. BMG LABTECH GmbH
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
- 9.6. Charles River Laboratories International, Inc.
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
- 9.7. Corning Incorporated
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
- 9.8. Danaher Corporation
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
- 9.9. Evotec SE
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
- 9.10. General Electric Company
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
- 9.11. Hamilton Company
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
- 9.12. Lonza Group Ltd.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
- 9.13. Merck KGaA
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
- 9.14. PerkinElmer, Inc.
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
- 9.15. Promega Corporation
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
- 9.16. Revvity, Inc.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
- 9.17. Roche Holding AG
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
- 9.18. Tecan Group Ltd.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
- 9.19. Thermo Fisher Scientific Inc.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
- 9.20. Yokogawa Electric Corporation
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
